Table 3.

Short-term and longterm achievement of MDA in patients with PsA treated with secukinumab in the randomized controlled trial, FUTURE 2.^*

Biologic Agent	Week	Anti-TNF Status of Patient Population	n	Dose	Patients with MDA, %	Reference
Secukinumab	16	Anti–TNF-naive	65	300 mg	34	Coates LC, et al, 2016¹⁹
			63	150 mg	32
			58	PBO	14
		Anti–TNF-IR	32	300 mg	16
			37	150 mg	8
			30	PBO	3
		Overall	97	300 mg	28
			100	150 mg	23
			88	PBO	10
	52	Anti–TNF-naive	63	300 mg	41
		Anti–TNF-naive	59	150 mg	39
		Anti–TNF-IR	30	300 mg	23
		Anti–TNF-IR	29	150 mg	21
		Overall	93	300 mg	35
		Overall	88	150 mg	33

↵* In the FUTURE 2 study, 397 patients with active PsA were randomized to subcutaneous secukinumab (300 mg, 150 mg, or 75 mg) or placebo at baseline, weeks 1, 2, and 3, and every 4 weeks from Week 4. Placebo patients were rerandomized to secukinumab 300 mg or 150 mg every 4 weeks from weeks 16 or 24, depending upon clinical response. The overall population includes both patients who are anti–TNF-naive and those who have previously used up to 3 anti-TNF agents but have had an inadequate response or stopped treatment because of safety or tolerability reasons. Data presented are as observed. Data from the 75 mg are not reported because that is not an approved dose of secukinumab. IR: inadequate responders; MDA: minimal disease activity; PBO: placebo; PsA: psoriatic arthritis; TNF: tumor necrosis factor.